TLSIW
HealthcareTriSalus Life Sciences Inc Wt Exp
$1.00+0.23 (+29.87%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving TLSIW Today?
No stock-specific AI insight has been generated for TLSIW yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.76$2.94
$1.00
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin-0.9%
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding—
TLSIW News
20 articles- TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver TumorsYahoo Finance·May 4, 2026
- TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference CallYahoo Finance·Apr 28, 2026
- TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific MeetingYahoo Finance·Apr 9, 2026
- TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical OfficerYahoo Finance·Apr 7, 2026
- TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor ModelsYahoo Finance·Mar 18, 2026
- TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference CallYahoo Finance·Feb 25, 2026
- TriSalus Life Sciences Announces Pricing of $40.0 Million Public OfferingYahoo Finance·Feb 20, 2026
- TriSalus Life Sciences Proposes Public OfferingYahoo Finance·Feb 19, 2026
- TriSalus Life Sciences Inc (TLSI) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ...Yahoo Finance·Nov 14, 2025
- TriSalus (TLSI) Q3 2025 Earnings Call TranscriptMotley Fool·Nov 13, 2025
- TriSalus Life Sciences, Inc. (TLSI) Reports Q3 Loss, Tops Revenue EstimatesYahoo Finance·Nov 13, 2025
- TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue GuidanceYahoo Finance·Nov 13, 2025
- TriSalus Life Sciences to Participate in Upcoming Investor ConferencesYahoo Finance·Nov 11, 2025
- TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025Yahoo Finance·Nov 10, 2025
- TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference CallYahoo Finance·Oct 30, 2025
- TriSalus Life Sciences to Participate in Upcoming September Investor ConferencesYahoo Finance·Aug 28, 2025
- TriSalus Life Sciences Inc (TLSI) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ...Yahoo Finance·Aug 13, 2025
- TriSalus Life Sciences, Inc. (TLSI) Reports Q2 Loss, Tops Revenue EstimatesYahoo Finance·Aug 12, 2025
- TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 GuidanceYahoo Finance·Aug 12, 2025
- TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization TechniqueYahoo Finance·Aug 11, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$1.00
Day High$0.00
Day Low$0.00
52 Week High$2.94
52 Week Low$0.76
52-Week Range
$0.76$2.94
$1.00
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin-0.9%
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding—
About TriSalus Life Sciences Inc Wt Exp
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company is headquartered in Westminster, Colorado.
HealthcareSURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICSURGICAL & MEDICAL INSTRUMENTS & APPARATUS
CIK—
Composite FIGI—
Share Class FIGI—